Vascular Endothelial Growth Factor (VEGF) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East

Vascular Endothelial Growth Factor (VEGF) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The global vascular endothelial growth factor (VEGF) market is on the cusp of significant growth, with a valuation of US$ 245 million at the close of 2024. By the end of 2031, the VEGF market is estimated to reach a substantial valuation of US$ 560 million, indicating a highly progressive growth trajectory.

A Pivotal Role in Disease Intervention

The versatility of VEGF molecules and advancements in research exploring their benefits in disease intervention have led to substantial growth in the market. Studies have demonstrated the potential of VEGF in treating renovascular disease (RVD) by coupling it with innovative carrier proteins. Enhanced renal function, reduced vascular resistance, and improved microvascular density have all been associated with VEGF-based treatments.

Investments in clinical trial investigations are expected to increase in the coming years, further bolstering market growth. Additionally, the use of intradermal VEGF-A mRNA in regenerative angiogenesis shows promise as a treatment for ischemic cardiovascular disease and diabetes, expanding the VEGF market from clinical interventions to a consumer-driven market.

Opportunities for VEGF Manufacturers

One of the notable opportunities for VEGF manufacturers lies in the treatment of peripheral vascular diseases. Recent research into gene co-delivery nanoparticles containing VEGF and nerve growth factors has shown promising results in improving blood perfusion, gene co-expression, and stable angiogenesis, offering new treatment options for peripheral vascular diseases.

Poly-l-lactide (PLA) loaded VEGF microparticles with a long-term release structure also hold potential in proangiogenic therapy, reducing the negative effects of multiple administrations and aiding in tissue remodeling, vasculogenesis, and angiogenesis.

The wide range of applications for VEGF presents lucrative opportunities for market players, with a growing trend in demand and sales.

Challenges in VEGF Market Expansion

Despite its potential, the short half-life of VEGF protein and challenges in selecting the route of administration for drug delivery have hindered its clinical success. Overcoming the limitations of VEGF's short half-life and chemical instability remains a challenge in the manufacturing process.

Country-wise Insights

U.S. VEGF Market: The U.S. dominated the North American VEGF market in 2024. Acquisitions by manufacturers and a growing focus on better treatment options have contributed to market growth.

German VEGF Market: Germany held a significant portion of the market share in Europe's vascular endothelial growth factor market in 2024.

The prominent players in Germany are actively expanding their manufacturing centers to offer products at competitive prices within the region, thereby playing a pivotal role in driving the growth of the German market.

China VEGF Market: In 2024, China held a significant market share in the East Asian vascular endothelial growth factor market.

Chinese leaders are increasingly viewing biologic contract manufacturing organizations (CMOs) as a viable option for bio manufacturing. These CMOs offer services to small- and medium-sized companies and invest in GMP facilities, making them an attractive choice.

Furthermore, established companies are expanding their manufacturing facilities, further bolstering the growth of the market in China.

Competitive Landscape

Key companies in the VEGF market include,
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Bio-Rad Laboratories, Inc.
• Bio-Techne [R&D Systems, Inc.]
• GenScript
• Miltenyi Biotec.
• Abcam PLC.
• Sino Biological Inc.
• Cell Signaling Technology, Inc.
• ACROBiosystems
• STEMCELL Technologies
• Creative Bioarray
• PeproTech
• Applied Biological Materials (ABM) Inc.
• GenWay Biotech
• Leadgene Biomedical, Inc.
• Boster Bio
• Prospec-Tany Technogene Ltd.
• Proteintech Group, Inc

Key Segments Covered in VEGF Industry Survey

VEGF Market by VEGF Type:
• Human VEGF
• Mouse VEGF
• Rat VEGF
• Rabbit VEGF
• Others VEGF

VEGF Market by Expression Host:
• CHO
• E. Coli
• HEK
• NSO
• Insect Cells
• Others

VEGF Market by Application:
• Cell Culture
• Cell-based Therapy
• Drug Development
• Gene Therapy
• Rare Disease treatment
• Wound Healing Research
• Combination Therapies
• Hematology Research
• Osteogenesis
• Anti-Angiogenic Therapy

VEGF Market by End User:
• Pharmaceutical & Biotechnology Companies
• Academic Institutes
• CMOs & CDMOs
• Other End Users

o Research Centers & Laboratories

o Hospital-attached Laboratories (HALs)

VEGF Market by Region:
• North America VEGF Market
• Latin America VEGF Market
• Europe VEGF Market
• South Asia VEGF Market
• East Asia VEGF Market
• Oceania VEGF Market
• Middle East & Africa VEGF Market

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.